A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
Standard
A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). / Grünwald, Viktor; Desar, Ingrid M E; Haanen, John; Fiedler, Walter; Mouritzen, Ulrik; Olsen, M W Brændholt; Herpen, van; Carla, M L.
in: ACTA ONCOL, Jahrgang 50, Nr. 1, 1, 2011, S. 121-126.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
AU - Grünwald, Viktor
AU - Desar, Ingrid M E
AU - Haanen, John
AU - Fiedler, Walter
AU - Mouritzen, Ulrik
AU - Olsen, M W Brændholt
AU - Herpen, van
AU - Carla, M L
PY - 2011
Y1 - 2011
N2 - sunitinib induces partial responses in 47% of patients with metastatic renal cell carcinoma (mRCC). However, the achievement of complete responses remains scarce and all patients will eventually develop progressive disease. Recombinant interleukin-21 (rIL-21) is a novel cytokine, which is believed to deliver sustained cellular anti-tumor response and the combination of both agents may work synergistically.
AB - sunitinib induces partial responses in 47% of patients with metastatic renal cell carcinoma (mRCC). However, the achievement of complete responses remains scarce and all patients will eventually develop progressive disease. Recombinant interleukin-21 (rIL-21) is a novel cytokine, which is believed to deliver sustained cellular anti-tumor response and the combination of both agents may work synergistically.
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Treatment Failure
KW - Drug Administration Schedule
KW - Recombinant Proteins/administration & dosage
KW - Protein-Tyrosine Kinases/antagonists & inhibitors
KW - Indoles/administration & dosage/adverse effects
KW - Kidney Neoplasms/drug therapy/pathology
KW - Pyrroles/administration & dosage/adverse effects
KW - Angiogenesis Inhibitors/administration & dosage/adverse effects
KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/pharmacokinetics
KW - Carcinoma, Renal Cell/drug therapy/secondary
KW - Hematologic Diseases/chemically induced
KW - Interleukins/administration & dosage/adverse effects
KW - Protein Kinase Inhibitors/administration & dosage/adverse effects
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Treatment Failure
KW - Drug Administration Schedule
KW - Recombinant Proteins/administration & dosage
KW - Protein-Tyrosine Kinases/antagonists & inhibitors
KW - Indoles/administration & dosage/adverse effects
KW - Kidney Neoplasms/drug therapy/pathology
KW - Pyrroles/administration & dosage/adverse effects
KW - Angiogenesis Inhibitors/administration & dosage/adverse effects
KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/pharmacokinetics
KW - Carcinoma, Renal Cell/drug therapy/secondary
KW - Hematologic Diseases/chemically induced
KW - Interleukins/administration & dosage/adverse effects
KW - Protein Kinase Inhibitors/administration & dosage/adverse effects
M3 - SCORING: Journal article
VL - 50
SP - 121
EP - 126
JO - ACTA ONCOL
JF - ACTA ONCOL
SN - 0284-186X
IS - 1
M1 - 1
ER -